Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. on October 20, 2010. The report addresses a corporate governance event regarding the appointment of a new Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointments.
Material Changes
On October 20, 2010, the Board of Directors appointed Eric I. Richman as President and Chief Executive Officer, effective immediately. Mr. Richman previously served as President and interim CEO since May 2010 and as President and Chief Operating Officer between March and May 2010.
Compensatory Arrangements and Outlook
In connection with his appointment, Mr. Richman received an option to purchase 125,000 shares of the Company's common stock under the 2007 Long-Term Incentive Compensation Plan. Key terms include:
- Exercise Price: $4.20 per share (closing price on NYSE Amex on the date of grant).
- Vesting Schedule: 25% per year in installments.
- First Vesting Date: The first anniversary of the date of grant.
The filing does not contain specific guidance, risk factors, or management commentary regarding future financial performance beyond the executive appointment.
Investor Verification Checklist
- Verify the exact vesting schedule and any acceleration clauses in the 2007 Long-Term Incentive Compensation Plan.
- Confirm the current stock price relative to the $4.20 exercise price to assess the option's intrinsic value.
- Review prior filings to understand the circumstances surrounding the previous interim CEO tenure.